GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabion SA (FRA:272) » Definitions » Cash Receipts from Tax Refunds

Mabion (FRA:272) Cash Receipts from Tax Refunds


View and export this data going back to 2021. Start your Free Trial

What is Mabion Cash Receipts from Tax Refunds?

Cash Receipts from Tax Refunds only applicable to companies reporting Cash Flow from Operations in direct method.


Mabion (FRA:272) Business Description

Industry
Traded in Other Exchanges
Address
ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.